Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone by Teply, Robyn et al.
© 2010 Teply et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Asthma and Allergy 2010:3 1–8
Journal of Asthma and Allergy

r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Current trends in the treatment of asthma: focus 
on the simultaneous administration of salmeterol/
fluticasone
robyn Teply1 
Jennifer Campbell2 
Daniel Hilleman1
1Creighton University School 
of Pharmacy and Health Professions, 
Omaha, Ne, USA; 2Creighton Cardiac 
Center, Omaha, Ne, USA
Correspondence: Daniel Hilleman 
Professor of Pharmacy Practice, 
Creighton University School of Pharmacy 
and Health Professions, 2500 California 
Plaza, Omaha, Ne 68178, USA 
Tel +1 402-280-4288 
email hilleman@creighton.edu
Abstract: Asthma is a chronic disease of the airways that affects over 20 million people in the 
United States. It is a complex disease that involves airway infiltration by different types of cells 
and cell mediators causing chronic inflammation of the airway as well as hyper-responsiveness 
and edema. Management of asthma symptoms often requires combination therapy with mul-
tiple medications. Long-acting beta-2 agonists and inhaled corticosteroids have become key 
medications in the prevention of asthma exacerbations. The bronchodilatory effects of the beta-2 
agonists coupled with the anti-inflammatory action of the corticosteroids combat the multi-
factorial causes of asthma. The combination inhaler containing salmeterol and fluticasone is 
one such product that has been proven safe and effective for asthma therapy.
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Introduction
Asthma is a condition that develops due to chronic inflammation and infiltration of 
cellular components such as mast cells, eosinophils, neutrophils, lymphocytes, and 
macrophages. Inflammation cascades into remodeling and hyper-responsiveness of the 
airways which in turn produce the symptoms of asthma.1 The clinical presentation of 
asthma includes wheezing, shortness of breath, chest tightness, and coughing which 
result from bronchoconstriction, hyper-responsiveness and airway edema. Several 
potential causes of asthma have been identified and include cytokine response, genetic 
component, and environmental stimuli such as airborne allergens, viral respiratory 
infections, tobacco smoke, and air pollution.2
Short-acting and long-acting bronchodilators have been a mainstay in asthma 
therapy. Acute asthma exacerbations are treated with short-acting bronchodilators 
and prevention of asthma attacks can be achieved through therapy management plans 
that include long-acting bronchodilators. To combat the inflammatory components of 
asthma, inhaled corticosteroids have been utilized to inhibit the recruitment, activation 
and function of pro-inflammatory cells.2 Due to the multi-factorial aspects of asthma, 
combination therapies with medications that have complementary mechanisms have 
become an important tool in asthma therapy. This paper will review the combination 
product that includes the long-acting beta-2 agonist salmeterol, and the inhaled cor-
ticosteroid fluticasone, which is one such asthma therapy.
It should be noted that there is a second combination product consisting of for-
moterol, a long-acting beta-2 agonist, and the inhaled corticosteroid, budesonide. 
The combination formoterol/budesonide product is available in fixed-dose and 
adjustable-dose formulations. A comparison of fixed-dose and adjustable-dose Journal of Asthma and Allergy 2010:3 
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formoterol/budesonide and fixed-dose salmeterol/fluticasone 
found all three to be equivalent in terms of asthma control 
and tolerability.3 Clinically, formoterol and salmeterol are 
similar with the exception that formoterol has a quicker 
onset of action (within 5 minutes similar to short acting 
beta agonists) compared to salmeterol (within 15 minutes).2 
This paper, however, will focus on the combination product 
salmeterol/fluticasone.
A literature search of the PubMed, Medline, Cochrane, 
and GoogleScholar databases was conducted to identify rel-
evant randomized controlled trials, systematic reviews, and 
meta-analyses. Search terms included salmeterol, fluticasone, 
long-acting beta agonists, LABA, inhaled corticosteroids, 
ICS, single inhaler, combination therapy, and asthma. The 
reference lists from the articles found were used to identify 
additional references.
Pharmacodynamics
Fluticasone is a synthetic corticosteroid with potent anti-
inflammatory properties. Inflammatory cell types includ-
ing mast cells, eosinophils, basophils, lymphocytes, and 
macrophages along with inflammation mediators including 
histamine, leukotrienes and cytokines are inhibited by corti-
costeroids. The inhibition of these inflammatory components 
reduces plasma exudation, mucous secretion, airway mem-
brane thickness, and hyper-responsiveness to stimuli.4,5
Salmeterol is a long-acting beta-2 adrenergic agonist 
which illicit its action partly through the stimulation of 
intracellular adenyl cyclase. Stimulation of this enzyme 
catalyzes the conversion of adenosine triphosphate to 
cyclic-3′,5′-adenosine monophosphate (cyclic AMP). This 
increase in cyclic AMP results in bronchodilation through 
relaxation of the bronchial smooth muscle and a reduction in 
the mediators responsible for hyper-responsiveness.4
In a study of 28 healthy volunteers, the potential for 
pharmacodynamic and pharmacokinetic interactions between 
inhaled salmeterol and fluticasone were examined by admin-
istering the drugs in combination and individually. After 
repeated administration of the treatments, no differences 
in pharmacodynamic action of the individual agents were 
seen when the drugs were co-administered. Parameters that 
were measured included 24-hour cortisol excretion, morn-
ing plasma cortisol levels, and lymphocyte beta-2 adreno-
ceptor polymorphism.6 In addition, it has also been shown 
in vitro that the co-administration of inhaled corticosteroids 
and long-acting beta-2 agonists has a synergistic effect. 
Mechanisms that account for this additive activity include 
the potential for corticosteroids to increase the number of 
beta-2 adrenoceptors and for increased binding affinity of 
the corticosteroids.7,8
Pharmacokinetics
Key pharmacokinetic parameters of the individual agents are 
listed in Table 1.4 The co-administration of these agents has 
not been shown to vary the pharmacokinetics with respect to 
peak serum concentration, time to peak serum concentration 
or elimination time.
In clinical studies of up to 12 weeks in duration, no differ-
ence in systemic effects to salmeterol or fluticasone was seen 
when comparing patients based on age. There are no gender 
differences in the pharmacokinetics of salmeterol or flutica-
sone. No formal kinetic studies have been done examining 
patients with renal or hepatic impairment. Due to the predomi-
nant hepatic metabolism of both agents, salmeterol and fluti-
casone may accumulate in patients with hepatic impairment 
and thus these patients should be monitored closely.4
Administration of beta-2 agonists, corticosteroids, anti-
histamines and theophylline had no significant effect on the 
pharmacokinetics of either fluticasone or salmeterol. Due to 
the metabolism of fluticasone via cytochrome P450 (CYP) 
3A4 isoenzymes, co-administration of agents that inhibit this 
hepatic enzyme may cause an increase in fluticasone plasma 
concentrations. Concurrent administration of fluticasone and 
the strong CYP 3A4 inhibitor ritonavir should be avoided 
and administration with other potent inhibitors should be 
monitored closely.4
Safety and tolerability
The safety and tolerability of the salmeterol/fluticasone com-
bination (SFC) combination is comparable to the individual 
components across all dosage strengths. The most common 
adverse events include respiratory tract infection and inflam-
Table  Pharmacokinetics of fluticasone and salmeterol
  Fluticasone Salmeterol
Peak plasma  
concentrations (minutes)
60–120 5
Mean peak steady-state  
plasma concentrations  
(pg/mL)
110 167
Protein binding (%) 91 96
Metabolism Hepatic via  
cytochrome P450  
isoenzyme 3A4
Hepatic via  
hydroxylation
Half-life (hours) 7.8 5.5
Primary elimination Feces FecesJournal of Asthma and Allergy 2010:3 
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mation, pharyngitis, oral candidiasis, bronchitis, headache, 
nausea, and vomiting.4,9,10 There were no clinically relevant 
changes in laboratory values with the use of inhaled SFC. The 
side effect profile was similar for children aged 4 to 11 years as 
was seen in adults and adolescents aged 12 years or greater.
The prescribing information for SFC does contain a 
black box warning due to an increased risk of asthma-related 
death seen with the use of long-acting beta agonist (LABA) 
monotherapy. In a large, randomized, double-blind, placebo-
controlled trial enrolling over 26,000 patients, 13 deaths were 
seen in the salmeterol group as compared to only 3 deaths in 
the placebo group during 28 weeks of therapy.11 As a result of 
this study, prescribers are urged to only prescribe salmeterol 
containing products to those patients that are not adequately 
controlled on other therapy options or whose disease severity 
is such that a two-medication regimen is warranted.4
Goal study
Previous studies comparing inhaler treatments of salmeterol/
fluticasone (SFC) to fluticasone or budesonide alone found 
that SFC was more effective than higher dose fluticasone or 
budesonide in preventing worsening asthma or improving 
peak expiratory flow rate (PEFR).3,12,13 The GOAL Study 
was the first trial to compare the effectiveness of two asthma 
control treatments (SFC versus fluticasone monotherapy) 
in achieving Global Initiative for Asthma (GINA)/National 
Asthma Education and Prevention Program (NAEPP) guide-
line based asthma control rather than improvement in any 
one measure of asthma.2,9,14 The 52-week study, involved 
3416 subjects, aged 12 years and older, who had uncontrolled 
asthma on current therapy. The study compared the safety 
and efficacy of predefined stepwise dose increases of SFC or 
fluticasone alone in achieving one of two study defined (and 
guideline based) measures of asthma control.9
Subjects were randomized to either SFC or fluticasone 
monotherapy. Each treatment group was subdivided into three 
treatment strata based on inhaled corticosteroids (ICS) use in 
the 6 months prior to study screening: stratum 1, no inhaled 
corticosteroid use; stratum 2, 500 µg of beclomethasone or 
equivalent; and stratum 3, 500 to 1000 µg of beclometha-
sone or equivalent. Phase 1 was a 12-week period in which the 
treatment dose was increased every 12 weeks until the subject 
achieved totally controlled asthma or the maximum dose was 
reached (SFC 50 µg/500 µg twice daily or fluticasone 500 µg 
twice daily). During Phase 2, subjects continued the dose of 
study medication they reached during Phase 1. At the end of 
Phase 2, there was an additional 4 week phase for subjects 
who did not achieve totally controlled asthma in either of 
the first two phases. In this phase, all subjects received oral 
prednisolone (0.5 mg/kg up to 60 mg/day) for 10 days in 
addition to SFC 50 µg /500 µg twice daily for 4 weeks.9
The primary study endpoint was the proportion of patients 
who achieved control during Phase 1. The study used two 
definitions of control based on GINA/NAEPP guideline 
measures of asthma control: well-controlled asthma and 
totally controlled asthma. Both endpoints were defined by 
composite measures that included PEFR, symptoms, rescue 
inhaler use, night-time awakenings due to asthma symptoms, 
number of exacerbations, number of emergency room visits, 
and adverse events. A well-controlled week was defined as 
having a symptom score of greater than 1 on no more than 
2 days in a week, using a rescue inhaler no more than 2 days 
in a week or on 4 or fewer occasions in a week, and having 
a PEFR  80% of predicted every day. A totally controlled 
week was defined as having no symptoms in a week, no use 
of rescue inhalers in a week, and a PEFR of  80% of pre-
dicted every day. Totally controlled asthma was defined as 
having 7 totally controlled weeks in an 8-week assessment 
period. Well-controlled asthma was defined as having 7 well-
controlled weeks within the 8 weeks. Any exacerbations, 
emergency room visits, and adverse events in any one week 
of the assessment period caused the entire 8-week assessment 
period to be defined as uncontrolled.9
The study also examined secondary endpoints including 
the percentages of patients attaining well-controlled and 
totally controlled asthma during Phase II, the maximum doses 
of inhaled corticosteroid, and the treatment times needed to 
attain the first well-controlled week and the first totally con-
trolled week, the rate of exacerbations (defined as requiring 
oral corticosteroids, an emergency room visit and/or hospi-
talization), and morning predose forced expiratory volume 
in the first second (FEV1) at clinic visits.
The study found that significantly greater proportions 
of subjects in all three strata of the SFC treatment group 
achieved well-controlled asthma and totally controlled 
asthma compared to subjects in the fluticasone treatment 
group.9,14 During Phase I, significantly more patients in all 
strata of the SFC treatment group reached well-controlled or 
totally controlled asthma compared to patients in the fluti-
casone only group. In stratum 1, 71% of patients in the SFC 
group versus 65% of patients in the fluticasone group attained 
well-controlled asthma (odds ratio [OR], 1.32; 95% confi-
dence interval [CI], 1.01 to 1.73; P = 0.039). Well-controlled 
asthma was attained by 69% versus 52% of patients in 
stratum 2, in the SFC and fluticasone groups respectively 
(OR, 2.13; 95% CI, 1.65 to 2.74; P  0.001).9Journal of Asthma and Allergy 2010:3 
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These research results were reflected in the GINA and 
NAEPP guideline updates. The 2007 update of the NAEPP’s 
guidelines recommend the combination treatment of a low 
to medium dose ICS with an inhaled LABA in preference 
to monotherapy with a high-dose ICS. In addition, the 2008 
update of the GINA guidelines recommends combination 
therapy of an ICS with a LABA over monotherapy with 
medium- or high-dose of an ICS.
More recently, research has evaluated the effectiveness 
of SFC compared to concurrent therapy with salmeterol 
and fluticasone via separate inhalers. Combination inhalers 
represent an important treatment option because national 
and international asthma treatment guidelines recommend 
that LABAs should only be used as add-on therapy with an 
ICS due to an increased risk of asthma related death or life-
threatening event. (GINA, NAEPP) The safety of LABAs has 
been a controversial issue for several years.15,16 The current 
Food and Drug Administration (FDA) black box warning 
on all LABAs (salmeterol, formoterol) is based on evidence 
from three sources: the SMART trial, a meta-analysis by 
Mann et al of asthma exacerbations in trials submitted to 
the FDA for approval of formoterol, and a meta-analysis of 
LABAs by Salpeter et al.2
As discussed earlier, the SMART trial evaluated the safety 
of salmeterol compared to placebo when added to current 
asthma therapy.11 The primary endpoint was a composite 
of respiratory-related death and respiratory-related, life-
threatening experiences which were defined as treatment 
requiring intubation and mechanical ventilation. Secondary 
endpoints included all-cause mortality, combined asthma-
related deaths and all cause hospitalizations. The study 
originally planned to randomize 60,000 subjects.11 A planned 
interim analysis was conducted after 26,355 subjects were 
randomized to treatment. Although the results of the analysis 
did not meet the pre-defined criteria for early termination, 
the sponsors terminated the trial. The interim analysis found 
that while there were no statistically significant differences 
between the placebo and salmeterol groups in terms of the 
primary endpoint, there were statistically significant dif-
ferences in the secondary endpoints. The salmeterol group 
experienced 37 asthma-related deaths versus 3 in the placebo 
group (P  0.05) and 37 combined asthma-related deaths or 
life-threatening experiences versus 22 in the placebo group 
(P  0.05).11
Additional analyses were done based on race and use of 
ICS. The analyses found that for Caucasian subjects (71% of 
the study population), there were no statistically significant 
differences between the salmeterol and placebo groups in 
either the primary endpoint (29 [1%] versus 28 [1%], 
respectively) or the secondary endpoints. Among African 
American subjects (18% of the study population), however, 
there were statistically significant differences between the 
salmeterol and placebo groups in the primary endpoint and in 
two of the secondary endpoints. In terms of the primary end-
point, 20 (1%) African Americans in the salmeterol group 
experienced a respiratory-related death or life-threatening 
experience versus 5 (1%) in the placebo group (P  0.05). 
Also, 19 (1%) African Americans in the salmeterol group 
experienced the secondary endpoint of combined asthma-
related death or life-threatening experience compared to 
4 (1%) in the placebo group (P  0.05). The reason for the 
higher incidence of events is unclear. The sub-analysis sug-
gested that African Americans patients may have had worse 
disease than Caucasian patients at screening as evidenced by 
lower PEFR, fewer patients using ICS therapy, and a higher 
percentage of emergency department visits. However, the 
study authors could not draw any conclusions as the study 
was not designed to evaluate the effect of other factors such 
as genetics, patient behaviors, concurrent medical conditions, 
and socioeconomic status on study outcomes.11
Post hoc analyses were done on the intent- to-treat popu-
lation to evaluate the effect of ICS therapy on the primary 
and secondary endpoints of the trial.11 Baseline ICS therapy 
was reported by 47% of patients in both the salmeterol and 
placebo groups. The analyses found that among subjects 
reporting baseline ICS therapy, there were no differences 
in the number of primary or secondary events between the 
salmeterol and placebo groups. Among subjects who reported 
no baseline ICS therapy, the salmeterol group experienced a 
greater number of primary and secondary events compared to 
the placebo group but the differences were only statistically 
significant for the secondary endpoints of asthma-related death 
(9 versus 0, for salmeterol and placebo, respectively; P  0.05) 
and combined asthma-related death or life-threatening experi-
ence (21 versus 9, for salmeterol and placebo, respectively; 
P  0.05). Nelson et al noted that since the effect of ICS on 
study outcomes was not part of the study design, they could 
not form a conclusion based on the post hoc analyses.11
Additionally, two meta-analyses found that treatment with 
LABAs increased the risk of asthma-related exacerbations. 
Mann et al reviewed three randomized controlled trials that 
were submitted to the FDA for approval of formoterol. The 
analysis found that patients treated with formoterol 24 µg 
twice daily had more serious asthma exacerbations than 
patients treated with formoterol 12 µg twice daily, placebo 
or albuterol. Because it was a post hoc exploratory study it Journal of Asthma and Allergy 2010:3 
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did not include a statistical analysis. However, the analysis 
concluded that treatment with formoterol 24 µg twice daily 
may be associated with an increase in serious asthma-related 
exacerbations.17
Salpeter et al performed a meta-analysis of 19 random-
ized controlled trials of LABAs (salmeterol, formoterol, 
eformoterol), including the SMART trial, with a total of 
33,826 asthma patients. They examined the Peto OR and 
risk differences between LABA treatment and placebo in 
asthma-related death, exacerbations requiring hospitaliza-
tion, and exacerbations requiring intubation and mechanical 
ventilation. The analysis found that compared to placebo, 
treatment with a LABA increased the risk of asthma-related 
deaths (OR, 3.5), exacerbations requiring hospitalization 
(OR, 2.6), and life threatening exacerbations (OR, 1.8). 
The study concluded that LABA therapy increases asthma-
related deaths and severe asthma exacerbations.15 Ernst et al 
cautioned that the Salpeter meta-analysis did not include 
studies that evaluated the benefit of adding LABAs to ICS 
therapy. The article noted that the Salpeter analysis failed to 
include two meta-analyses that evaluated the risk of severe 
exacerbations in patients on ICS therapy with LABA add-
on therapy. The trials in these two meta-analyses required 
patients to remain on ICS therapy.18
The exact cause of this increased risk is unknown. LABAs 
do not provide any clinically significant anti-inflammatory 
effect. It has been suggested that LABA monotherapy may 
worsen disease control by masking worsening or persistent 
airway inflammation through decreasing signs and symptoms 
of an exacerbation.2,19 Lazarus et al evaluated the use of salme-
terol as replacement therapy in patients with persistent asthma 
who were controlled on an ICS. The study of 165 patients 
aged 12 to 64, found that although patients in the salmeterol 
group experienced improved airway function, symptoms, and 
a decreased use of rescue inhalers, their rate of exacerbations 
and treatment was similar to patients in the placebo group.20
McIvor et al evaluated the hypothesis that LABAs may 
mask airway inflammation in a randomized, controlled, cross-
over study of 17 patients who were controlled on high dose 
ICS therapy. The study compared the effect of salmeterol 
50 µg twice daily to matching placebo, with a progressive 
reduction in ICS therapy, on the extent of inflammation (mea-
sured by sputum eosinophilia) that developed prior to an exac-
erbation. Eosinophilia, a biomarker for airway inflammation, 
was used because it is unaffected by the bronchodilator effect 
of salmeterol. Patients in the salmeterol group were able to 
significantly reduce their ICS dose compared to the placebo 
group prior to an exacerbation (P = 0.01). As the ICS dose 
decreased, eosinophilia counts trended higher. Compared to 
the placebo arm, the salmeterol arm had higher eosinophilia 
counts in the 3 weeks prior to an exacerbation but they 
were statistically significantly higher only in the week prior 
to an exacerbation (mean eosinophilia count 9.3 ± 17.6% 
versus 19.9 ± 29.8%, placebo and salmeterol, respectively; 
P = 0.006). Patients’ FEV1 and symptoms remained stable 
even with the higher eosinophilia counts. The study con-
cluded that the bronchodilating and symptom relief effects 
of salmeterol treatment may mask increasing inflammation 
and worsening asthma control.19
Single inhaler versus separate 
inhalers
As previously discussed, research indicates that LABAs when 
used as add-on therapy to ICS therapy can provide better 
asthma control than higher dose ICS monotherapy.2,9,14 Evi-
dence suggests that adherence to asthma treatment decreases 
with complexity.12,21 In particular, multiple inhalers are con-
fusing to patients.12,21 Additionally, patients have a tendency 
to stop ICS therapy when symptoms improve.12 Combination 
inhalers may provide a means for improving asthma control 
while increasing patient compliance with therapy and ensur-
ing that LABAs are given in addition to ICS therapy.12,21
Several studies (Table 2) demonstrated that a combined 
ICS/LABA inhaler is as effective and safe as concurrent 
therapy with separate inhalers.9,22 In a 12-week study, 
Bateman et al evaluated the efficacy and tolerability of SFC 
versus concurrent treatment with salmeterol and fluticasone 
in separate inhalers in subjects who were symptomatic on 
current therapy.23 244 subjects, aged 12 years and older, 
were randomized to SFC 50 µg/100 µg twice daily versus 
concurrent therapy with salmeterol 50 µg twice daily plus 
fluticasone 100 µg twice daily. The primary end-point was 
the mean morning PEFR with secondary end-points of FEV1, 
Table  Combined inhaler vs concurrent inhalers
Study 
 
 
 
Adjusted mean 
change from  
baseline morning 
PEFR (L/min)
CI 
 
 
 
P value 
 
 
 
SFC S + F
Aubier24 35 33 90% (–10, 4) 0.535
Bateman23 42 33 90% (–17, 0) 0.098
Chapman26 43 36 90% (–13, 0) 0.114
van den Berg22 33 28 90% (–10, 0) 0.103
Abbreviations: Ci, confidence interval; PeFr, peak expiratory flow rate; 
SFC, salmeterol/fluticasone; S + F, salmeterol and fluticasone monotherapies.Journal of Asthma and Allergy 2010:3 
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rescue inhaler use, and symptom score. The study found no 
statistical difference between treatments for the primary 
endpoint of PEFR or for any of the secondary end-points. 
The mean PEFR improved by 42 and 33 L/min for SFC and 
separate inhalers respectively (P = 0.098).23 At the end of 
the trial, 60% of the subjects in the SFC group compared 
to 64% in the separate inhaler group were asymptomatic. 
Additionally, the study found that the SFC inhaler was as 
well tolerated as the separate inhalers. 15% of subjects in the 
single inhaler group had an adverse event compared to 14% 
in the separate inhaler group.23
Van den Berg et al studied the safety and efficacy of the 
SFC inhaler compared to concurrent therapy with separate 
inhalers in children aged 4 to 11 years who were symp-
tomatic on ICS therapy. The primary endpoint was mean 
morning PEF. Secondary endpoints included mean evening 
PEFR, FEV1, and symptom scores for day and night-time. 
Two hundred fifty-seven subjects were randomized to SFC 
50 µg/100 µg twice daily versus concurrent therapy with 
salmeterol 50 µg twice daily plus fluticasone 100 µg twice 
daily. The study found that the single inhaler was clinically 
equivalent to concurrent therapy with separate inhalers in 
improvement of mean morning PEFR (P = 0.103). Addi-
tionally, the results for the secondary endpoints also dem-
onstrated clinical equivalence between the two treatments: 
improvement in mean evening PEFR (P = 0.164), improve-
ment in FEV1 (P = 0.052), and improvement in daytime 
and night-time symptom scores (P = 0.904 and P = 0.779 
respectively).22
Two additional studies indicated that the SFC inhaler 
was clinically equivalent to concurrent therapy with separate 
inhalers. Aubier et al evaluated SFC compared to concurrent 
therapy with separate inhalers in subjects requiring high dose 
inhaled corticosteroids within the 4 weeks prior to random-
ization. Five hundred and three subjects were randomized 
to one of three treatment groups: SFC 50 µg/500 µg twice 
daily, salmeterol 50 µg and fluticasone 500 µg given by 
separate inhalers twice daily, and fluticasone 500 µg twice 
daily. The primary efficacy end-point of mean morning PEFR 
was evaluated over a 12-week treatment period. Safety was 
evaluated over a 28-week period. The combination inhaler 
group had slightly better improvement in mean morning 
PEFR from baseline compared to concurrent therapy (12% 
improvement versus 10%, respectively) but the difference 
was not statistically significant. However, as in previous 
studies, Aubier et al found that SFC therapy was superior to 
fluticasone alone (P = 0.001).24,25
In another 28-week trial, Chapman et al compared 
combined with concurrent therapy in 371 subjects, aged 13 
and older, who were symptomatic on therapy that included 
ICS. Subjects were randomized to SFC 50 µg/250 µg twice 
daily or salmeterol 50 µg and fluticasone 250 µg given by 
separate inhalers twice daily. Mean morning PEFR, the pri-
mary efficacy end-point, was measured over the first 12 weeks. 
Safety data were collected over the 28-week treatment period. 
The results of the first 12 weeks, showed equivalency in 
adjusted mean morning PEF improvement between the two 
treatments (90% CI, –13 to 0 L/min; P = 0.114).25,26
Additional research suggests that treatment with a combi-
nation inhaler may be superior to concurrent therapy.25,27 The 
four trials discussed above demonstrated the clinical equiva-
lency of SFC compared to concurrent therapy with separate 
inhalers. The data from these studies trended towards the use 
of the single inhaler. Using these data, Nelson et al performed a 
meta-analysis to further evaluate the benefit of a single inhaler 
compared to separate inhalers.25 The primary endpoint was the 
change in mean morning PEF from baseline over 12 weeks. 
The analysis included mean change in evening PEF, and clinic 
FEV1. In addition, the mean percentage of symptom-free days 
and nights, individually and together, was evaluated. The 
analysis found that in the primary endpoint, SFC demonstrated 
a superior effect of 5.4 L/min over the 12-week treatment 
period compared to concurrent therapy with separate inhalers 
(P = 0.006; 95% CI, 1.52 to 9.17). In terms of the secondary 
endpoints, the study found that SFC also had a statistically 
significant improvement in mean evening PEF of 6.11 L/min 
compared to the concurrent inhalers (P  0.001; 95% CI, 2.48 
to 9.75). SFC showed a trend towards improvement in FEV1 
compared to concurrent therapy with separate inhalers but it 
was not statistically significant (P = 0.54; 95% CI, 0.00 to 
0.08). No difference was found between the two treatments 
in terms of symptom free days, nights, or both.25
Angus et al performed a retrospective longitudinal analy-
sis of a national primary care database and evaluated the use 
of rescue inhalers (short-acting beta agonists, SABA) and 
oral corticosteroids (OC) in SFC compared to therapy with 
beclomethasone and a LABA in separate inhalers. Patients 
with a diagnosis of asthma who were 12 to 55 years old were 
included in the analysis if they had a prescription for SFC 
or beclomethasone and LABA in separate inhalers (date of 
the first prescription for SFC or beclomethasone and LABA 
was defined as the index event). Additionally the patients had 
to have 6 months of data prior to and after the index event 
and no prescription for a LABA prior to the index event. Journal of Asthma and Allergy 2010:3 
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Patients were excluded if they had a diagnosis of COPD. 
The study identified 211 patients using SFC and 377 patients 
using beclomethasone and LABA. The primary end-points 
were the number of doses of SABA prescribed and the per-
centage of patients who were prescribed at least one course 
of OCs. The treatment groups were statistically different at 
baseline in terms of age, gender, and rescue inhaler use. The 
SFC group was younger compared to the beclomethasone 
and LABA treatment group (33 versus 37 years, respectively; 
P = 0.0007) and also had fewer female patients (48.8% versus 
61.3%, SFC and beclomethasone and LABA respectively; 
P = 0.0034). In the preindex period, the median number of 
SABA dosages was 400 for the SFC group and 500 for the 
beclomethasone and LABA group (P = 0.038).28
The analysis found that the difference in the postindex 
median number of doses of SABA prescribed was statisti-
cally significant. In the SFC group, the median number of 
doses decreased by 100, while in the beclomethasone and 
LABA group the median number remained the same (median 
difference –100; 95% CI, –200 to –60; P  0.0001). In 
addition, the difference in the percentage of patients in SFC 
group (13.7%) requiring at least one course of OCs postin-
dex compared to the percentage in the beclomethasone and 
LABA group (20.7%) was statistically significant (difference 
6.9%; 95% CI, –13.1 to –0.8; P = 0.036).27
Conclusion
Asthma is a chronic disease of the airways that affect approxi-
mately 23.4 million people in the US.2 It is a complex disease 
that involves airway infiltration by different types of cells and 
cell mediators causing chronic inflammation of the airway as 
well as hyper-responsiveness and edema.29 Management of 
asthma symptoms often requires combination therapy with 
multiple medications.
Previous research demonstrated that combination therapy 
with an ICS and LABA was superior in efficacy to higher 
dose ICS monotherapy.3,12,13 More recent research has demon-
strated that SFC therapy is clinically equivalent to concurrent 
salmeterol and fluticasone therapy with separate inhalers.22–26 
Two analyses also suggest that SFC therapy may provide 
more benefit compared to concurrent therapy with separate 
inhalers.25,28 This has important treatment implications. Stud-
ies indicate that as the number of asthma inhalers increases, 
treatment adherence declines.12,21 In addition, many patients 
will stop ICS therapy once they are less symptomatic.12 Com-
bination therapy with SFC may simplify asthma treatment 
and help improve treatment adherence.
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